Aligos Therapeutics, Inc. (NASDAQ:ALGS) Receives $41.50 Average Price Target from Analysts

Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) have been assigned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $37.20.

A number of equities analysts recently commented on the company. Westpark Capital assumed coverage on Aligos Therapeutics in a report on Thursday, March 26th. They set a “buy” rating and a $48.00 target price for the company. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Aligos Therapeutics in a report on Wednesday, March 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Aligos Therapeutics in a report on Monday, April 20th. Cantor Fitzgerald assumed coverage on Aligos Therapeutics in a report on Thursday. They set an “overweight” rating and a $20.00 target price for the company. Finally, Jefferies Financial Group upgraded Aligos Therapeutics to a “strong-buy” rating in a report on Thursday, March 26th.

Aligos Therapeutics Trading Up 2.0%

Shares of NASDAQ:ALGS opened at $5.71 on Friday. The business has a 50-day moving average price of $6.91 and a 200 day moving average price of $7.92. The company has a market capitalization of $35.34 million, a price-to-earnings ratio of -0.66 and a beta of 2.28. Aligos Therapeutics has a 12-month low of $5.12 and a 12-month high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS) last announced its earnings results on Thursday, May 7th. The company reported ($2.21) EPS for the quarter, beating analysts’ consensus estimates of ($2.29) by $0.08. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%.The company had revenue of $2.83 million during the quarter, compared to analysts’ expectations of $0.25 million. As a group, equities research analysts predict that Aligos Therapeutics will post -7.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aligos Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. NorthCrest Asset Manangement LLC purchased a new position in Aligos Therapeutics during the 3rd quarter valued at about $98,000. Rockefeller Capital Management L.P. boosted its stake in shares of Aligos Therapeutics by 900.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after buying an additional 9,000 shares during the period. Susquehanna International Group LLP purchased a new position in shares of Aligos Therapeutics in the 3rd quarter valued at about $99,000. HRT Financial LP purchased a new position in shares of Aligos Therapeutics in the 4th quarter valued at about $106,000. Finally, DRW Securities LLC purchased a new position in shares of Aligos Therapeutics in the 4th quarter valued at about $111,000. 60.43% of the stock is currently owned by hedge funds and other institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.